Skip to main content
. 2009 Feb 6;106(8):2729–2734. doi: 10.1073/pnas.0813175106

Fig. 1.

Fig. 1.

Expression of ICOS and FOXP3 by CD4 T cells in peripheral blood of prostate cancer patients. (A) In healthy donors (n = 10), ≈2% of CD4 T cells express ICOS (Left) and 5% of CD4 T cells express FOXP3 (Right). (B) In untreated prostate cancer patients (n = 10), ≈3% of CD4 T cells express ICOS (Left) and 43% of CD4 T cells express FOXP3 (Right). A representative figure from one healthy donor (A) and one untreated prostate cancer patient (B) is shown, with numbers indicating mean percentages (± standard deviations) calculated from samples from 10 healthy donors and 10 patients with untreated prostate cancer.